Urovant Sciences Ltd

Urovant Sciences — Jefferies Virtual Health Care Conference 2020

27 slides from Urovant Sciences's conference presentation, Jun 2, 2020

  1. Slide 1: Jefferies Virtual Health Care Conference

    UROVANT SCIENCES Jefferies Virtual Health Care Conference June 2, 2020 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements, including without limitation, statements related to: our plans to file for approval of vibegron with the FDA, and the timing of such filing and the likelihood of FDA approval; our ability to successfully develop Vibegr

  3. Slide 3: Investment Highlights

    1. Subject to the approval by the FDA, including FDA approval of the inclusion of urgency data, rapid onset of action data and a single convenient once-daily dose in the label Investment Highlights UROVANT Vibegron: NDA accepted March 2020 Positive EMPOWUR Phase 3 results announced in March 2019 PDU

  4. Slide 4: Urovant Pipeline

    Urovant Pipeline Development and Acquisition of Differentiated Treatments Supports Vision of Becoming a Leading Urology Company DRUG CANDIDATE INDICATION PHASE 1 PHASE 2 PHASE 3 UPCOMING MILESTONE vibegron Overactive Bladder (OAB) PDUFA date December 26, 2020 OAB in Men with BPH Phase 3 top-line dat

  5. Slide 5: Vibegron Clinical Data and Development

    VIBEGRON CLINICAL DATA AND DEVELOPMENT

  6. Slide 6: Extensive Clinical Development Program

    Extensive Clinical Development Program Three successful, placebo-controlled studies completed in over 4,000 patients achieving all primary and secondary endpoints Robust clinical pharmacology package (21 studies complete) Long-term toxicity and carcinogenicity studies complete In-licensed from Merck

  7. Slide 7: EMPOWUR Results: Strong Efficacy Across All OAB Endpoints

    EMPOWUR Results: Vibegron Demonstrated Strong Efficacy Across All OAB Endpoints Week 12 LS Mean Change from Baseline (Placebo-Adjusted) Endpoint Vibegron n p-value UUI Episodes2 -0.6 383 <0.0001 Micturitions2 -0.5 492 <0.001 Urgency Episodes3 -0.7 492 0.0020 Total Incontinence Episodes3 -0.7 383 <0.

  8. Slide 8: Rapid Onset and Sustained Benefit in Phase 3 Trial

    Rapid Onset and Sustained Benefit in Phase 3 Trial Table 14.2.2.1.2, Full Analysis Set for Incontinence, CFB Least squares mean Covariates included in the mixed model for repeated measures are study visit, sex, region, baseline number of UUI, and treatment by study visit interaction Change in Averag

  9. Slide 9: >50% of Patients Achieved ≥75% Reduction in UUI Episodes at Week 12

    >50% of Patients Achieved ≥75% Reduction in UUI Episodes at Week 12 P-value is active vs placebo NS1 P < 0.001 P < 0.05 P < 0.05 1. P-values for the difference in proportions between active and placebo were calculated using the Cochran-Mantel-Haenszel risk difference estimate stratified by OAB Type

  10. Slide 10: Vibegron was Well Tolerated

    Vibegron was Well Tolerated Table 14.3.1.15, Safety Analysis Set. Represents number of patients. Vibegron has not demonstrated a QTc signal at any dose, including 400 mg (highest tested dose) Completed ambulatory blood pressure study with no statistically significant increase in daytime ambulatory s

  11. Slide 11: Vibegron: Potential for Category-Defining Differentiation in OAB

    Vibegron: Significant Potential For Category-Defining Differentiation1 in OAB vibegron2 ACh mirabegron Rapid onset of efficacy (2 weeks) Potential efficacy claim for urgency3 Potential broader efficacy claims No CYP2D6 drug-drug interactions Some Single convenient crushable dose4 No known dementia r

  12. Slide 12: OAB Market and Vibegron Commercial Strategy

    OAB MARKET AND VIBEGRON COMMERCIAL STRATEGY

  13. Slide 13: Large Market

    Large Market ~14 million patients discuss symptoms with a physician2 ~3.3 million patients on prescription therapy3 More than 30 million Americans over 40 years old suffer from bothersome symptoms of OAB1 1. Coyne et al., EpiLUTS 2007 2. Benner et al., J Urol, 2009 3. BIQVIA (IMS) New to Brand Data

  14. Slide 14: β3 Agonist (Mirabegron) Is Gaining U.S. OAB Market Share

    β3 Agonist (Mirabegron) Is Gaining U.S. OAB Market Share 1. IQVIA Launch Edition October 2012 through March 2020 2. Astellas reported projected net sales of mirabegron in the Americas of $821M for FY 2019 , ended March 31, 2020 (vs. $728M FY 2018) 3. Urovant analysis and estimate based on mirabegron

  15. Slide 15: Goal: Establish Vibegron as the OAB Brand of Choice

    Goal: Establish Vibegron as the OAB Brand of Choice Start with a targeted effort with high prescribing PCPs Ensure broad payor coverage Activate patients to request vibegron Deploy a fully scaled, best-in-class sales force in Urology and Long-Term Care Key Elements of Commercial Strategy Explore co-

  16. Slide 16: Urologists, LTC, High Prescribing PCPs Write >50% of OAB Prescriptions

    Urologists, LTC, High Prescribing PCPs Write >50% of OAB Prescriptions Other 13% Long-Term Care 17% Urologist 20% NPPA 16% OB/GYN 5% PCP 29% OAB Rx 2018 Volume by Specialty1 Urologists, LTC, and High Prescribing PCPs account for >50% of all OAB prescriptions Urologists prescribe 30% of all β3s Urolo

  17. Slide 17: Formulary Acceptance will be Key to Vibegron Success

    Formulary Acceptance will be Key to Vibegron Success β3 category enjoys wide payor coverage under Medicare Part D and commercial plans Establishing market access team with deep experience in Urology to obtain formulary coverage 1. IMS PayerTrak Dec 2018 2. IQVIA (IMS) NPA data ending Dec 2018. TRx b

  18. Slide 18: Vibegron Could Potentially Lower Overall Costs of Care

    Vibegron Could Potentially Lower Overall Costs of Care Annual Direct Medical Costs for OAB Patients are >2.5X HIGHER Than Non-OAB Patients1 Admission to a nursing facility: 2.0x greater for incontinent women2 3.2x greater for incontinent men2 19%-50% of OAB patients experienced a fall over a 1-year

  19. Slide 19: Growth Opportunities

    GROWTH OPPORTUNITIES DO NOT DUPLICATE, DETAIL, DISTRIBUTE, TRANSMIT, FORWARD, ORUSE IN ANY PROMOTIONALMANNER

  20. Slide 20: IBS-Associated Pain and OAB in Men with BPH Lifecycle Opportunities

    IBS-Associated Pain and OAB in Men with BPH Represent Lifecycle Opportunities with Significant Market Potential 40 million Men aged 50 – 80 years old with BPH >4 million Treated BPH patients in the U.S. OAB in Men with BPH > 2 million U.S. BPH patients with co-morbid OAB IBS population based upon: 1

  21. Slide 21: Gene Therapy Overview: URO-902

    Gene Therapy Overview: URO-902 Market Overview Potential to address an unmet need for OAB patients who have failed oral pharmacological therapies and are concerned with potential urinary retention after BOTOX or any “toxin” effect or surgical intervention Currently, there are no FDA-approved gene th

  22. Slide 22: Urovant Sciences Milestones

    Urovant Sciences Milestones 2020FDA acceptance of vibegron NDA Preparing for the successful launch of vibegron Further build out commercial leadership team Top-line results of vibegron trial in IBS-associated pain URO-902 complete phase 2a cohort 1 enrollment 2H 2020 PDUFA for vibegron in OAB ü 2021

  23. Slide 23: Investment Highlights

    1. Subject to the approval by the FDA, including FDA approval of the inclusion of urgency data, rapid onset of action data and a single convenient once-daily dose in the label Investment Highlights UROVANT Vision: Become A Leading Urology Specialty Company Vibegron: NDA accepted March 2020 Positive

  24. Slide 24: Appendix

    APPENDIX DO NOT DUPLICATE, DETAIL, DISTRIBUTE, TRANSMIT, FORWARD, ORUSE IN ANY PROMOTIONALMANNER

  25. Slide 25: OAB+BPH: URO-901-3005 Phase 3

    OAB+BPH: URO-901-3005 Phase 3 POPULATION Men with OAB and BPH DURATION 12-week primary efficacy treatment period; 24-week efficacy and safety period plus 6-month extension KEY ENDPOINTS Co-primary endpoints: Change from baseline in daily micturitions (urination) and urgency Key secondary endpoint: N

  26. Slide 26: IBS Associated Pain: URO-901-2001 Phase 2a

    IBS Associated Pain: URO-901-2001 Phase 2a POPULATION Women with IBS with predominantly diarrhea (IBS-D) or mixed episodes of diarrhea and constipation (IBS-M) DURATION 12-week primary efficacy treatment period; total observation period 14 weeks (includes 2-week safety follow-up) KEY ENDPOINTS Prima

  27. Slide 27: Gene Therapy OAB: URO-902-2001 Phase 2a Proof-of-Concept Study

    Gene Therapy OAB: URO-902-2001 Exploratory Phase 2a Proof-of-Concept Study POPULATION Women 40-79 years old with OAB and urge urinary incontinence (non-childbearing potential) DURATION 12-week primary efficacy treatment period; total observation period of 48 weeks KEY ENDPOINTS Change at week 12 in

Urovant Sciences — Jefferies Virtual Health Care Conference 2020 on 6ix